Adc Therapeutics Sa (ADCT) Stock Price, Quote & News

Latest News on ADCT

Feb 3, 2025, 4:05 PM EST - 5 weeks ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Jan 30, 2025, 7:15 AM EST - 6 weeks ago

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Dec 30, 2024, 4:30 PM EST - 2 months ago

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

Dec 12, 2024, 2:03 PM EST - 3 months ago

ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL

$ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma$

Dec 11, 2024, 7:30 AM EST - 3 months ago

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

$ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma$

Dec 9, 2024, 7:30 AM EST - 3 months ago

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

Dec 6, 2024, 7:30 AM EST - 3 months ago

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

Nov 9, 2024, 11:01 AM EST - 4 months ago

ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 1:14 PM EST - 4 months ago

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

Nov 7, 2024, 7:30 AM EST - 4 months ago

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

Nov 5, 2024, 9:47 AM EST - 4 months ago

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

Nov 4, 2024, 7:15 AM EST - 4 months ago

ADC Therapeutics to Present at November Investor Conferences

Oct 31, 2024, 7:15 AM EDT - 4 months ago

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

Sep 3, 2024, 7:15 AM EDT - 6 months ago

ADC Therapeutics to Present at Upcoming Investor Conferences

Aug 11, 2024, 9:26 AM EDT - 7 months ago

ADC Therapeutics SA (ADCT) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:30 AM EDT - 7 months ago

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Jul 30, 2024, 7:15 AM EDT - 8 months ago

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024

Jul 8, 2024, 2:00 AM EDT - 8 months ago

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

Jun 27, 2024, 7:15 AM EDT - 9 months ago

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

May 30, 2024, 7:15 AM EDT - 10 months ago

ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 15, 2024, 7:15 AM EDT - 10 months ago

ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 9, 2024, 7:15 AM EDT - 11 months ago

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference

May 6, 2024, 11:04 AM EDT - 11 months ago

ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript

May 6, 2024, 7:30 AM EDT - 11 months ago

ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants

May 6, 2024, 6:10 AM EDT - 11 months ago

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

$ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma$

May 6, 2024, 6:00 AM EDT - 11 months ago

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

$ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma$